Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 296

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons

Kelley, Colleen F., Acevedo-Quiñones, Maribel, Agwu, Allison L., Avihingsanon, Anchalee, Benson, Paul, Blumenthal, Jill, Brinson, Cynthia, Brites, Carlos, Cahn, Pedro, Cantos, Valeria D., Clark, Jesse, Clement, Meredith, Creticos, Cathy, Crofoot, Gordon, Diaz, Ricardo S., Doblecki-Lewis, Susanne, Gallardo-Cartagena, Jorge A., Gaur, Aditya, Grinsztejn, Beatriz, Hassler, Shawn, Hinojosa, Juan Carlos, Hodge, Theo, Kaplan, Richard, Lacerda, Marcus, LaMarca, Anthony, Losso, Marcelo H., Valdez Madruga, José, Mayer, Kenneth H., Mills, Anthony, Mounzer, Karam, Ndlovu, Nkosiphile, Novak, Richard M., Perez Rios, Alma, Phanuphak, Nittaya, Ramgopal, Moti, Ruane, Peter J., Sánchez, Jorge, Santos, Breno, Schine, Patric, Schreibman, Tanya, Spencer, LaShonda Y., Van Gerwen, Olivia T., Vasconcelos, Ricardo, Vasquez, Jose Gabriel, Zwane, Zwelethu, Cox, Stephanie, Deaton, Chris, Ebrahimi, Ramin, Wong, Pamela, Singh, Renu, Brown, Lillian B., Carter, Christoph C., Das, Moupali, Baeten, Jared M., Ogbuagu, Onyema·2025·New England Journal of Medicine

Abstract

BACKGROUND: Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of human immunodeficiency virus (HIV) infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in cisgender men, transgender women, transgender men, and gender-nonbinary persons is unclear. METHODS: In this phase 3, double-blind, randomized, active-controlled trial, we randomly assigned participants in a 2:1 ratio to receive subcutaneous lenacapavir every 26 weeks or daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF). The primary efficacy analysis compared the incidence of HIV infection in the lenacapavir group with the background HIV incidence in the screened population. The secondary efficacy analysis compared the incidence of HIV infection in the lenacapavir group with that in the F/TDF group. RESULTS: Among 3265 participants who were included in the modified intention-to-treat analysis, HIV infections occurred in 2 participants in the lenacapavir group (0.10 per 100 person-years; 95% confidence interval [CI], 0.01 to 0.37) and in 9 participants in the F/TDF group (0.93 per 100 person-years; 95% CI, 0.43 to 1.77). The background HIV incidence in the screened population (4634 participants) was 2.37 per 100 person-years (95% CI, 1.65 to 3.42). The incidence of HIV infection in the lenacapavir group was significantly lower than both the background incidence (incidence rate ratio, 0.04; 95% CI, 0.01 to 0.18; P<0.001) and the incidence in the F/TDF group (incidence rate ratio, 0.11; 95% CI, 0.02 to 0.51; P = 0.002). No safety concerns were identified. A total of 26 of 2183 participants (1.2%) in the lenacapavir group and 3 of 1088 (0.3%) in the F/TDF group discontinued the trial regimen because of injection-site reactions. CONCLUSIONS: The HIV incidence with twice-yearly lenacapavir was significantly lower than the background incidence and the incidence with F/TDF. (Funded by Gilead Sciences; PURPOSE 2 ClinicalTrials.gov number, NCT04925752.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2411858

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 296

Metadata

Authors
Kelley, C. F., Acevedo-Quiñones, M., Agwu, A. L., Avihingsanon, A., Benson, P., Blumenthal, J., Brinson, C., Brites, C., Cahn, P., Cantos, V. D., Clark, J., Clement, M., Creticos, C., Crofoot, G., Diaz, R. S., Doblecki-Lewis, S., Gallardo-Cartagena, J. A., Gaur, A., Grinsztejn, B., Hassler, S., Hinojosa, J. C., Hodge, T., Kaplan, R., Lacerda, M., LaMarca, A., Losso, M. H., Valdez Madruga, J., Mayer, K. H., Mills, A., Mounzer, K., Ndlovu, N., Novak, R. M., Perez Rios, A., Phanuphak, N., Ramgopal, M., Ruane, P. J., Sánchez, J., Santos, B., Schine, P., Schreibman, T., Spencer, L. Y., Van Gerwen, O. T., Vasconcelos, R., Vasquez, J. G., Zwane, Z., Cox, S., Deaton, C., Ebrahimi, R., Wong, P., Singh, R., Brown, L. B., Carter, C. C., Das, M., Baeten, J. M., & Ogbuagu, O.
Venue
New England Journal of Medicine
Published
2025-04-03
Volume
392
Issue
13
Pages
1261-1276
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4404784297
Cited by
296
References
31
FWCI
93.98
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. https://app.cochat.ai/papers/10.1056/nejmoa2411858
The paper
Kelley, C. F., Acevedo-Quiñones, M., Agwu, A. L., Avihingsanon, A., Benson, P., Blumenthal, J., Brinson, C., Brites, C., Cahn, P., Cantos, V. D., Clark, J., Clement, M., Creticos, C., Crofoot, G., Diaz, R. S., Doblecki-Lewis, S., Gallardo-Cartagena, J. A., Gaur, A., Grinsztejn, B., . . . Ogbuagu, O. (2025). Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2411858

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.